Nasonex, Flonase Detail Aids Make Unproven Superiority Claims - DDMAC Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks Schering-Plough, GlaxoSmithKline to pull detail material containing “unsubstantiated,” and “false and misleading” claims.
You may also be interested in...
GSK’s Veramyst To Launch By Late May
Flonase follow-on is indicated for treatment of seasonal and perennial allergic rhinitis in adults and children two years of age and older.
GSK Drops Suit Against FDA Approval Of Generic Flonase
Par and Roxane resume shipment of generic fluticasone following the expiration of a temporary restraining order.
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee